Johnson & Johnson Investor Information
Johnson & Johnson Investor Information
3 FOLLOWERS
Get all the news and updates from Johnson & Johnson investors, sales, research and more! Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people.
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
Johnson & Johnson Investor Information
by Johnson & Johnson News Releases
7M ago
NEW BRUNSWICK, N.J. --(BUSINESS WIRE)--Sep. 18, 2023-- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 17 th   to review third-quarter results. Joseph J. Wolk , Executive Vice President and Chief Financial Officer and Jessica ..read more
Visit website
Treatment with RYBREVANT® (amivantamab-vmjw) and Lazertinib Plus Chemotherapy Showed Durable Progression-Free Survival in Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Johnson & Johnson Investor Information
by Johnson & Johnson News Releases
7M ago
..read more
Visit website
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Erdafitinib for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer with Susceptible FGFR Alterations
Johnson & Johnson Investor Information
by Johnson & Johnson News Releases
7M ago
..read more
Visit website
Janssen Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of BALVERSA® (erdafitinib) for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations
Johnson & Johnson Investor Information
by Johnson & Johnson News Releases
8M ago
..read more
Visit website
Janssen Submits Supplemental Biologics License Application to the U.S. Food and Drug Administration Seeking Approval of RYBREVANT® (amivantamab-vmjw) in Combination with Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic EGFR Exon 20 Insertion Mutation-Positive Non Small Cell Lung Cancer
Johnson & Johnson Investor Information
by Johnson & Johnson News Releases
8M ago
..read more
Visit website
Johnson & Johnson to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Johnson & Johnson Investor Information
by Johnson & Johnson News Releases
8M ago
..read more
Visit website
Johnson & Johnson Announces Preliminary Results of Kenvue Inc. Exchange Offer
Johnson & Johnson Investor Information
by Johnson & Johnson News Releases
8M ago
..read more
Visit website
European Commission Approves Reduced Dosing Frequency for Janssen’s Bispecific Antibody TECVAYLI®▼ (teclistamab)
Johnson & Johnson Investor Information
by Johnson & Johnson News Releases
8M ago
..read more
Visit website
U.S. FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate), the First-And-Only Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
Johnson & Johnson Investor Information
by Johnson & Johnson News Releases
8M ago
..read more
Visit website
U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
Johnson & Johnson Investor Information
by Johnson & Johnson News Releases
8M ago
..read more
Visit website

Follow Johnson & Johnson Investor Information on FeedSpot

Continue with Google
Continue with Apple
OR